IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma

The US FDA has granted Fast Track designation to IDEAYA’s development program investigating darovasertib, a potential first-in-class protein kinase C inhibitor, for use in combination with crizotinib, for the treatment of adult patients with metastatic uveal melanoma.